10-Q: Tempus AI Q2 Revenue Soars 90% Amid Strategic Acquisitions

Tempus AI reports significant revenue growth in Q2 2025, driven by the Ambry Genetics acquisition and increased demand for its genomics and data services, despite continued net losses.

Summary

• Total net revenue increased by 90% to $314.6 million for the three months ended June 30, 2025, up from $166.0 million in the same period of 2024.
• Genomics revenue grew by 115% to $241.8 million in Q2 2025, primarily due to the acquisition of Ambry Genetics and increased Oncology test volumes (from approximately 66,500 to 84,000 tests).
• Data and services revenue increased by 36% to $72.8 million in Q2 2025, driven by increased demand for Insights products and the Pathos Foundation Model agreement.
• Net loss significantly decreased to $42.8 million in Q2 2025 from $552.2 million in Q2 2024.
• Adjusted EBITDA improved to $(5.6) million in Q2 2025 from $(31.2) million in Q2 2024.
• Acquired Ambry Genetics Corporation for $375.0 million in cash and 4,843,136 shares of Class A common stock, expanding testing capabilities into hereditary cancer screening and new disease categories.
• Acquired Deep 6 AI, Inc. for $4.3 million in cash and $13.1 million in Class A common stock, enhancing AI-powered clinical trial matching.
• Completed a private offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 in July 2025, using proceeds to repay $293.5 million of Term Loan Facilities and for general corporate purposes.
• Reincorporated from a Delaware corporation to a Nevada corporation, effective August 7, 2025.
• Entered into a Controlled Equity Offering SM Sales Agreement on August 8, 2025, to sell up to $500.0 million of Class A common stock through at-the-market offerings.
• Granted 2,569,600 performance-based restricted stock units (PSUs) to executive officers on August 7, 2025, tied to compound revenue growth and total shareholder return performance.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and a significant reduction in net loss and improved Adjusted EBITDA, indicating positive operational momentum. Strategic acquisitions and new capital raise strengthen its financial position and market reach. However, it continues to incur losses and negative operating cash flow, and faces ongoing legal challenges and market risks, which temper the overall positive sentiment.

Positives

• Total net revenue increased by 90% to $314.6 million in Q2 2025 compared to Q2 2024, indicating strong top-line growth.
• Genomics revenue surged 115% to $241.8 million in Q2 2025, significantly boosted by the Ambry Genetics acquisition and increased Oncology test volumes.
• Average revenue per Oncology test increased from approximately $1,500 in Q2 2024 to $1,580 in Q2 2025, driven by improved Medicare reimbursement rates.
• Data and services revenue grew 36% to $72.8 million in Q2 2025, primarily due to increased demand for Insights products and the Pathos Foundation Model agreement.
• Net loss significantly reduced to $42.8 million in Q2 2025 from $552.2 million in Q2 2024, demonstrating improved financial performance.
• Adjusted EBITDA improved from $(31.2) million in Q2 2024 to $(5.6) million in Q2 2025, nearing profitability on this non-GAAP measure.
• Strategic acquisitions of Ambry Genetics and Deep 6 AI expand testing capabilities, disease categories, and AI-powered solutions, strengthening market position.
• Successful $750.0 million Convertible Senior Notes offering provides significant capital and satisfies a junior capital raise requirement, preventing a 0.50% per annum interest rate increase on existing debt.
• New At-the-Market (ATM) sales agreement provides flexibility for future capital raises up to $500.0 million.
• New performance-based restricted stock units (PSUs) for executives align incentives with company revenue growth and total shareholder return.

Negatives

• Continued net loss of $42.8 million in Q2 2025 and $110.9 million for the six months ended June 30, 2025.
• Negative cash flow from operating activities of $(61.5) million for the six months ended June 30, 2025.
• Significant cash used in investing activities of $(385.3) million for the six months ended June 30, 2025, primarily due to acquisitions.
• Increased interest expense to $21.6 million in Q2 2025 from $13.3 million in Q2 2024, due to new debt facilities.
• Accumulated deficit of $2.3 billion as of June 30, 2025.
• Reliance on securing reimbursement from payers and government health benefits programs for genomics testing, with payment received on approximately 55% of clinical oncology NGS tests across all payers performed from January 1, 2022, through December 31, 2023.
• Exposure to macroeconomic conditions that may adversely impact earlier-stage biotechnology companies, affecting demand for Data and services products.
• Ongoing legal proceedings, including patent infringement lawsuits and a federal securities class-action lawsuit, create uncertainty and potential costs.
• The dual-class common stock structure grants CEO Eric Lefkofsky significant control (30 votes per Class B share), potentially limiting the influence of Class A shareholders.

Risks

• Ability to secure reimbursement from payers and government health benefits programs for clinical genomic testing, as a substantial majority of tests are clinical in nature.
• Impact of macroeconomic conditions, including new tariffs and restrictive trade policies, on the life sciences industry and the company's operating costs and demand for its products.
• Dependence on continued high levels of investment in research and development and technology to develop new products and expand the platform.
• Ability to successfully integrate acquired businesses (Ambry Genetics, Deep 6 AI) and realize the expected benefits and synergies from these acquisitions.
• Potential for dilution to Class A common stock holders upon conversion of the Convertible Senior Notes and from future equity raises through the ATM sales agreement.
• Counterparty risk with capped call transactions related to the Convertible Senior Notes, as the company's exposure is unsecured.
• Ongoing legal proceedings, including patent infringement claims by Guardant Health Inc. and a federal securities class-action lawsuit alleging false or misleading statements, could result in significant costs or adverse outcomes.
• Government investigations related to compliance with the False Claims Act, Anti-Kickback statute, and the Medicare 14-Day Rule could have a material adverse effect on the business.
• The dual-class common stock structure concentrates voting power with CEO Eric Lefkofsky, which could delay or prevent a change of control or other corporate actions desired by other shareholders.
• Nevada's combinations with interested stockholders statutes could apply, potentially delaying, deferring, or preventing certain business combinations or hostile takeovers.
• Exclusive forum provisions in the articles of incorporation for certain legal actions may limit where stockholders can bring claims, potentially increasing litigation costs for stockholders.
• Inflation risk and inflationary factors, such as increases in raw material and overhead costs, could impair operating results and gross margins.

Future Outlook

The company expects to incur additional operating losses in the near future as it continues to invest in new offerings, expand its sales organization, and increase marketing efforts. Capital expenditure requirements may also increase if additional laboratory capacity is needed due to growing demand for its products. The company believes its current cash and cash equivalents, marketable equity securities, and anticipated cash flows from operations, inclusive of the proceeds from the recent Convertible Senior Notes offering, will be sufficient to meet its anticipated cash requirements for more than twelve months from the date of this Quarterly Report on Form 10-Q.

Management Comments

• "We strive to combine deep healthcare expertise, providing next-generation diagnostics across multiple disease areas, with leading technology capabilities, harnessing the power of data and analytics to help personalize medicine."
• "We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare."
• "We believe Intelligent Diagnostics represent the future of precision medicine, informing more personalized and data-driven therapy selection and development."
• "Our financial performance relies heavily on our ability to secure reimbursement from payers and government health benefits programs."
• "We will continue to invest significantly in various efforts aimed at improving our average reimbursement, including performing clinical studies to generate evidence of clinical utility, seeking regulatory approval for our tests, and opening additional lab locations."
• "We expect to maintain high levels of investment in our technology over the coming years as we continue to develop new features to support our current and future business needs."

Industry Context

Tempus AI operates at the intersection of healthcare technology, genomics, and artificial intelligence, aiming to revolutionize precision medicine through 'Intelligent Diagnostics.' This strategy differentiates it from traditional diagnostic labs by integrating diverse patient data (clinical, molecular, imaging) with AI. The company's recent acquisitions, such as Ambry Genetics, signify a strategic expansion into new disease categories like hereditary cancer screening, pediatrics, and cardiology, aligning with broader industry trends towards comprehensive diagnostic solutions. Its collaborations with major pharmaceutical and biotechnology companies (e.g., AstraZeneca, GSK, Recursion) for data licensing and clinical trial support underscore the growing importance of real-world data and AI-driven insights in drug discovery, development, and patient matching within the life sciences sector.

Management Changes

Corporate Governance

Legal Proceedings

• Received a subpoena from the Office of the Ohio Attorney General on May 19, 2022, requesting billing and patient records for Ohio Medicaid patients. Responsive documents were provided in June 2022, with no additional inquiry since.
• Received a Civil Investigative Demand (CID) from the U.S. Attorney's Office for the Eastern District of New York on March 4, 2024, requesting documents related to compliance with the False Claims Act, Anti-Kickback statute, and the Medicare 14-Day Rule. Responsive documents have been provided, with no additional inquiry since the last production.
• Guardant Health Inc. filed a patent infringement complaint on June 11, 2024, in the U.S. District Court for the District of Delaware, alleging that Tempus xF, Tempus xF+, Tempus xM Monitor, and Tempus xM MRD products infringe five Guardant U.S. patents. The complaint seeks injunctive relief, unspecified monetary damages (including enhanced damages), a future mandatory royalty, costs, and attorneys' fees.
• Guardant Health Inc. separately sought a Declaratory Judgment against Tempus on January 17, 2025, in the U.S. District Court for the District of Delaware regarding the veracity of certain advertisements Guardant has published.
• Tempus filed multiple counterclaims against Guardant on March 14, 2025, under the Lanham Act and related state statutes, alleging that Guardant's advertisements were false and misleading.
• Tempus filed a separate patent infringement complaint against Guardant in the U.S. District Court for the Southern District of California, alleging that certain Guardant products infringe U.S. Patent Nos. 12,112,839, 11,640,859, 10,957,041, and 10,991,097. All cases are pending.
• A federal securities class-action lawsuit, Shouse v. Tempus AI, Inc. et al, was filed on June 12, 2025, in the United States District Court for the Northern District of Illinois, naming the Company, CEO Eric Lefkofsky, and CFO James Rogers as defendants. The complaint alleges false or misleading statements or omissions between August 6, 2024, and May 27, 2025. The company believes the complaint is without merit and intends to defend vigorously.

Related Party Transactions

• Subleases a portion of office space to a related party on a month-to-month basis (sublease income was insignificant).
• Master Agreement with Pathos AI, Inc. (co-founded by CEO Eric Lefkofsky), amended February 12, 2024, for drug development commercialization efforts. The company received a warrant to purchase approximately 15% of Pathos's equity.
• Order Form with Pathos (April 17, 2025) for Foundation Model development and data licensing: Pathos will pay Tempus $200 million over three years (including a $50 million upfront payment in April 2025) for a data license. Tempus will provide a secure cloud environment (Pathos pays the first $60 million of compute costs), and Tempus will receive a license to use the Foundation Model. Tempus will pay Pathos $35 million.
• Recognized $15.9 million in revenue from Pathos for Q2 2025 ($16.5 million for the six months ended June 30, 2025).
• Amount due to related parties was $25.0 million as of June 30, 2025 (up from $0 at December 31, 2024).
• Amount due from related parties was $2.2 million as of June 30, 2025 (down from $4.3 million at December 31, 2024).
• Related party asset (representing future services from Pathos) was $2.5 million current and $22.5 million non-current as of June 30, 2025.
• Related party deferred revenue was $36.7 million current and $0 non-current as of June 30, 2025.
• Joint Venture Agreement with SoftBank Group Corporation (SB Tempus Corp.) was formed on May 18, 2024, and closed on July 18, 2024. Each party contributed ¥15 billion ($95.2 million) for a 50% stake.
• Data License Agreement with SB Tempus: Tempus granted a limited, non-exclusive license for de-identified data in Japan for ¥7.5 billion ($47.9 million), recognized as deferred revenue over the term ending March 31, 2026. Recognized $6.2 million in revenue in Q2 2025 ($12.5 million for the six months ended June 30, 2025).
• Intellectual Property Agreement with SB Tempus: Tempus received ¥7.5 billion ($47.9 million) for a non-exclusive license to certain technologies in Japan, amortized into Other income (expense), net over three years. Recognized $4.0 million in income in Q2 2025 ($8.0 million for the six months ended June 30, 2025).

Stakeholder Impact

• Shareholders: Potential for dilution from convertible notes and ATM offering. Class A shareholders have limited voting power due to the dual-class structure. Ongoing legal proceedings (securities class action, patent disputes) create uncertainty regarding future share price and potential liabilities.
• Employees: Stock-based compensation, including new performance-based restricted stock units (PSUs), aligns incentives with company performance. Acquisitions (Ambry, Deep 6) integrate new workforces, potentially impacting organizational structure and culture.
• Customers: Expanded product offerings (hereditary testing, AI-powered trial matching) and strategic collaborations aim to improve patient care and drug development support, potentially enhancing customer value.
• Creditors: New convertible notes and credit facilities increase debt, but proceeds were used to repay existing debt, managing liquidity. Compliance with debt covenants is crucial for maintaining financial stability.
• Suppliers: Non-cancelable arrangements for data licenses and cloud computing services represent significant purchase obligations, indicating continued reliance on key suppliers.

Next Steps

• Continue to invest in new assay development and expansion into new disease areas.
• Maintain high levels of investment in technology to continually improve user experience and data efficiency.
• Continue efforts to improve average reimbursement rates, including performing clinical studies to generate evidence of clinical utility and seeking regulatory approval for tests.
• File an information statement on Schedule 14C with the SEC regarding the approved Amended and Restated Articles, which will become effective 20 calendar days after mailing.
• Potentially offer and sell additional Class A common stock through the Controlled Equity Offering SM Sales Agreement.
• Executive performance-based restricted stock units (PSUs) will vest based on performance goals for calendar years 2025, 2025-2026, and 2025-2027.

Key Dates

Recommendation

Tempus AI demonstrates strong revenue growth and improved profitability metrics (reduced net loss, better Adjusted EBITDA), driven by strategic acquisitions and expanding data/genomics services. The recent capital raise through convertible notes strengthens its liquidity. However, the company remains unprofitable, has negative operating cash flow, and faces significant legal challenges, including a securities class-action lawsuit and multiple patent disputes. The dual-class share structure also concentrates voting power, which some investors may view negatively. Given the mixed financial performance, ongoing legal uncertainties, and the long-term nature of its strategic investments, a 'hold' recommendation is appropriate for a seasoned investor, awaiting clearer signs of sustained profitability and resolution of legal risks.

Keywords

Healthcare Technology, Genomics, Artificial Intelligence, AI Applications, Clinical Trials, Data Licensing, Precision Medicine, Biotechnology, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Acquisition, Convertible Notes, Dual-Class Stock, Risk Management, Corporate Governance, Nasdaq